Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark

20 Arrested In California Medicaid Fraud Case
Twenty people in California were arrested on Thursday "in a $4.6-million Medi-Cal fraud scheme that law enforcement officials allege used unlicensed individuals to provide in-home nursing care for disabled patients," The Los Angeles Times reports. "About 75 patients, many of them children with cerebral palsy or developmental disabilities, were treated at home or at school by the unlicensed individuals who stole identities to pose as licensed nurses, according to the United States Attorney"s office." Those arrested "are among 42 defendants named in a 41-count indictment," in what United States Attorney Thomas O"Brien calls "the largest single case alleging Medi-Cal fraud ever filed in the state of California" (Abdulrahim, 7/9).
generic viagra online
FDA Classifies Medtronic Voluntary February Recall For Intrepid™ Intervertebral Body Fusion Device As Class II
Medtronic, Inc. (NYSE: MDT) announced that the U.S. Food and Drug Administration (FDA) has classified its voluntary recall action of the Intrepid™ Intervertebral Body Fusion Device as a Class II recall. Medtronic initiated a voluntary recall of the product on February 6, 2009, and communicated the risk to physicians and hospitals. As of the date of this news release, all unused product has been retrieved and Medtronic has received confirmation of notification from all affected physicians and hospitals.
News of the day
First Confirmed Case Of 2009 H1N1 Flu In Navajo County
Navajo County Public Health Services District officials announced today the first case of 2009 H1N1 in Navajo County. The Arizona Department of Health Services Lab confirmed that an 18 year old patient at Little Colorado Medical Center tested positive for the illness. The patient has subsequently been treated and released.
Medical Devices

European Urology July Issue Reviews Prostate Screening Studies

The July issue of European Urology, the official journal of the European Association of Urology, features an editorial by Lars Holmberg comparing the results from the European Randomised Study of Screening for Prostate Cancer (ERSPC) with the results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) In the editorial, Professor Holmberg writes that "The studies illustrate that the price to pay for 20% reduction in prostate cancer deaths is high; overdiagnosis and overtreatment are great problems. The answers lie in improving the PSA test or finding biomarkers that effectively separate aggressive cancers from slow-growing ones. We identify some priorities in the discussion about PSA testing." Another article of interest in this issue is "Testosterone and Prostate Cancer: Revisiting Old Paradigms" by H. Isbarn et al. The notion that pathologic prostate growth, benign or malignant, can be stimulated by androgens is a commonly held belief - but one without scientific basis. In the article, Dr. Isbarn writes that, "We therefore conducted a Medline search to identify articles addressing the relationship between testosterone and the risk of prostate cancer development. Although large prospective studies addressing the long-term effect of testosterone treatment are needed to either refute or corroborate the hypothesis, the available literature strongly suggests that testosterone treatment neither increases the risk of prostate cancer diagnosis in normal men nor causes cancer recurrence in men who were successfully treated for prostate cancer." Next month, European Urology will publish the EAU position statement on screening for prostate cancer which takes into consideration the recent scientific information on randomised screening studies on prostate cancer (Schrç¶der et al, NEJM 2009). The EAU adopts the conclusions of the ERSPC study and recognises the benefit of screening in terms of mortality reduction, as well as the adverse effects of overdiagnosis and overtreatment of prostate cancers which could be quantified for the first time in the setting of a randomised screening study. Lindy Brouwer European Association of Urology


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009